vs
伊萨（ESAB）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
伊萨的季度营收约是Royalty Pharma plc的1.2倍（$727.8M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 7.5%，领先26.9%），伊萨同比增速更快（8.5% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 2.8%）
ESAB（全称Elektriska Svetsnings-Aktiebolaget）是一家美国与瑞典合资的跨国工业企业，主营焊接、切割设备及配套耗材的研发、生产与销售，为全球制造业、基建等多领域客户提供专业可靠的工业解决方案，在全球工业市场拥有较高知名度。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ESAB vs RPRX — 直观对比
营收规模更大
ESAB
是对方的1.2倍
$622.0M
营收增速更快
ESAB
高出3.7%
4.8%
净利率更高
RPRX
高出26.9%
7.5%
两年增速更快
RPRX
近两年复合增速
2.8%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $727.8M | $622.0M |
| 净利润 | $54.8M | $214.2M |
| 毛利率 | 37.0% | — |
| 营业利润率 | 14.6% | 62.4% |
| 净利率 | 7.5% | 34.4% |
| 营收同比 | 8.5% | 4.8% |
| 净利润同比 | 2.1% | 2.9% |
| 每股收益（稀释后） | $0.90 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESABRPRX
| Q4 25 | $727.8M | $622.0M | ||
| Q3 25 | $715.6M | $609.3M | ||
| Q2 25 | $678.1M | $578.7M | ||
| Q1 25 | — | $568.2M | ||
| Q4 24 | $670.8M | $593.6M | ||
| Q3 24 | $673.3M | $564.7M | ||
| Q2 24 | $707.1M | $537.3M | ||
| Q1 24 | $689.7M | $568.0M |
净利润ESABRPRX
| Q4 25 | $54.8M | $214.2M | ||
| Q3 25 | $66.9M | $288.2M | ||
| Q2 25 | $67.4M | $30.2M | ||
| Q1 25 | — | $238.3M | ||
| Q4 24 | $53.7M | $208.2M | ||
| Q3 24 | $68.2M | $544.0M | ||
| Q2 24 | $82.9M | $102.0M | ||
| Q1 24 | $60.0M | $4.8M |
毛利率ESABRPRX
| Q4 25 | 37.0% | — | ||
| Q3 25 | 37.2% | — | ||
| Q2 25 | 37.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 38.5% | — | ||
| Q3 24 | 37.7% | — | ||
| Q2 24 | 38.2% | — | ||
| Q1 24 | 37.0% | — |
营业利润率ESABRPRX
| Q4 25 | 14.6% | 62.4% | ||
| Q3 25 | 15.2% | 70.1% | ||
| Q2 25 | 16.2% | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | 16.6% | 60.9% | ||
| Q3 24 | 15.7% | — | ||
| Q2 24 | 16.9% | 50.2% | ||
| Q1 24 | 16.0% | -13.0% |
净利率ESABRPRX
| Q4 25 | 7.5% | 34.4% | ||
| Q3 25 | 9.3% | 47.3% | ||
| Q2 25 | 9.9% | 5.2% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | 8.0% | 35.1% | ||
| Q3 24 | 10.1% | 96.3% | ||
| Q2 24 | 11.7% | 19.0% | ||
| Q1 24 | 8.7% | 0.8% |
每股收益（稀释后）ESABRPRX
| Q4 25 | $0.90 | $0.49 | ||
| Q3 25 | $1.09 | $0.67 | ||
| Q2 25 | $1.10 | $0.07 | ||
| Q1 25 | — | $0.55 | ||
| Q4 24 | $0.87 | $0.46 | ||
| Q3 24 | $1.11 | $1.21 | ||
| Q2 24 | $1.35 | $0.23 | ||
| Q1 24 | $0.98 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $218.2M | $618.7M |
| 总债务越低越好 | $1.3B | $9.0B |
| 股东权益账面价值 | $2.1B | $9.7B |
| 总资产 | $4.9B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.63× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ESABRPRX
| Q4 25 | $218.2M | $618.7M | ||
| Q3 25 | $258.2M | $938.9M | ||
| Q2 25 | $291.3M | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $249.4M | $929.0M | ||
| Q3 24 | $253.7M | $950.1M | ||
| Q2 24 | $228.5M | $1.8B | ||
| Q1 24 | $76.5M | $843.0M |
总债务ESABRPRX
| Q4 25 | $1.3B | $9.0B | ||
| Q3 25 | $1.1B | $8.9B | ||
| Q2 25 | $1.1B | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $1.1B | $7.6B | ||
| Q3 24 | $1.1B | $7.6B | ||
| Q2 24 | $1.1B | $7.6B | ||
| Q1 24 | $992.8M | $6.1B |
股东权益ESABRPRX
| Q4 25 | $2.1B | $9.7B | ||
| Q3 25 | $2.1B | $9.6B | ||
| Q2 25 | $1.9B | $9.5B | ||
| Q1 25 | — | $9.8B | ||
| Q4 24 | $1.8B | $10.3B | ||
| Q3 24 | $1.8B | $10.3B | ||
| Q2 24 | $1.7B | $9.8B | ||
| Q1 24 | $1.6B | $9.9B |
总资产ESABRPRX
| Q4 25 | $4.9B | $19.6B | ||
| Q3 25 | $4.4B | $19.3B | ||
| Q2 25 | $4.2B | $18.3B | ||
| Q1 25 | — | $17.6B | ||
| Q4 24 | $4.0B | $18.2B | ||
| Q3 24 | $4.1B | $18.0B | ||
| Q2 24 | $4.0B | $17.7B | ||
| Q1 24 | $3.8B | $16.1B |
负债/权益比ESABRPRX
| Q4 25 | 0.63× | 0.92× | ||
| Q3 25 | 0.51× | 0.93× | ||
| Q2 25 | 0.55× | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 0.60× | 0.74× | ||
| Q3 24 | 0.59× | 0.74× | ||
| Q2 24 | 0.63× | 0.78× | ||
| Q1 24 | 0.61× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $81.5M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $70.3M | — |
| 自由现金流率自由现金流/营收 | 9.7% | — |
| 资本支出强度资本支出/营收 | 1.5% | — |
| 现金转化率经营现金流/净利润 | 1.49× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $238.0M | — |
8季度趋势，按日历期对齐
经营现金流ESABRPRX
| Q4 25 | $81.5M | $827.1M | ||
| Q3 25 | $46.6M | $702.6M | ||
| Q2 25 | $35.4M | $364.0M | ||
| Q1 25 | — | $596.1M | ||
| Q4 24 | $126.9M | $742.5M | ||
| Q3 24 | $101.0M | $703.6M | ||
| Q2 24 | $83.0M | $658.2M | ||
| Q1 24 | $44.5M | $664.6M |
自由现金流ESABRPRX
| Q4 25 | $70.3M | — | ||
| Q3 25 | $37.4M | — | ||
| Q2 25 | $28.1M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $102.2M | — | ||
| Q3 24 | $90.4M | — | ||
| Q2 24 | $74.0M | — | ||
| Q1 24 | $37.1M | — |
自由现金流率ESABRPRX
| Q4 25 | 9.7% | — | ||
| Q3 25 | 5.2% | — | ||
| Q2 25 | 4.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 15.2% | — | ||
| Q3 24 | 13.4% | — | ||
| Q2 24 | 10.5% | — | ||
| Q1 24 | 5.4% | — |
资本支出强度ESABRPRX
| Q4 25 | 1.5% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 1.6% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | 1.1% | — |
现金转化率ESABRPRX
| Q4 25 | 1.49× | 3.86× | ||
| Q3 25 | 0.70× | 2.44× | ||
| Q2 25 | 0.53× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | 2.36× | 3.57× | ||
| Q3 24 | 1.48× | 1.29× | ||
| Q2 24 | 1.00× | 6.45× | ||
| Q1 24 | 0.74× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESAB
| Consumable Products | $477.9M | 66% |
| Equipment Products | $249.9M | 34% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
